ProductNum | picture | CAS No. | Name and description | Size | Formula | Quick order |
---|---|---|---|---|---|---|
GC31951-5mg |
|
477202-00-9 |
Ipilimumab (MDX-010)
|
0 | C6742H9972N1732O2004S40 | |
GC31950-25mg |
|
64924-67-0 |
Halofuginone hydrobromide (RU-19110 (hydrobromide))
|
0 | C16H18Br2ClN3O3 | |
GC31950-10mg |
|
64924-67-0 |
Halofuginone hydrobromide (RU-19110 (hydrobromide))
|
0 | C16H18Br2ClN3O3 | |
GC31950-5mg |
|
64924-67-0 |
Halofuginone hydrobromide (RU-19110 (hydrobromide))
|
0 | C16H18Br2ClN3O3 | |
GC31950-10mM(1mLinDMSO) |
|
64924-67-0 |
Halofuginone hydrobromide (RU-19110 (hydrobromide))
|
0 | C16H18Br2ClN3O3 | |
GC31949-100mg |
|
2098884-53-6 |
PAT-1251 Hydrochloride
|
0 | C18H18ClF4N3O3 | |
GC31949-50mg |
|
2098884-53-6 |
PAT-1251 Hydrochloride
|
0 | C18H18ClF4N3O3 | |
GC31949-25mg |
|
2098884-53-6 |
PAT-1251 Hydrochloride
|
0 | C18H18ClF4N3O3 | |
GC31949-10mg |
|
2098884-53-6 |
PAT-1251 Hydrochloride
|
0 | C18H18ClF4N3O3 | |
GC31949-5mg |
|
2098884-53-6 |
PAT-1251 Hydrochloride
|
0 | C18H18ClF4N3O3 | |
GC31947-10mg |
|
129424-08-4 |
ICI 211965 (ZM-211965)
|
0 | C24H23NO2S | |
GC31947-5mg |
|
129424-08-4 |
ICI 211965 (ZM-211965)
|
0 | C24H23NO2S | |
GC31947-1mg |
|
129424-08-4 |
ICI 211965 (ZM-211965)
|
0 | C24H23NO2S | |
GC31946-200mg |
|
3166-62-9 |
Methylbenactyzium Bromide
|
0 | C21H28BrNO3 | |
GC31946-100mg |
|
3166-62-9 |
Methylbenactyzium Bromide
|
0 | C21H28BrNO3 | |
GC31946-50mg |
|
3166-62-9 |
Methylbenactyzium Bromide
|
0 | C21H28BrNO3 | |
GC31946-10mM(1mLinDMSO) |
|
3166-62-9 |
Methylbenactyzium Bromide
|
0 | C21H28BrNO3 | |
GC31945-5mg |
|
— |
Hosenkoside B
|
0 | — | |
GC31945-10mM(1mLinDMSO) |
|
— |
Hosenkoside B
|
0 | — | |
GC31944-20mg |
|
136564-67-5 |
LTD4 antagonist 1
|
0 | C31H32F3N3O5S | |